|
1
|
Herrmann E, Bierer S and Wülfing C: Update
on systemic therapies of metastatic renal cell carcinoma. World J
Urol. 28:303–309. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Athar U and Gentile TC: Treatment options
for metastatic renal cell carcinoma: A review. Can J Urol.
15:3954–3966. 2008.PubMed/NCBI
|
|
3
|
Lam JS, Leppert JT, Belldegrun AS and
Figlin RA: Novel approaches in the therapy of metastatic renal cell
carcinoma. World J Urol. 23:202–212. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
McDermott DF, Regan MM, Clark JI, Flaherty
LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff
MS, et al: Randomized phase III trial of high-dose interleukin-2
versus subcutaneous interleukin-2 and interferon in patients with
metastatic renal cell carcinoma. J Clin Oncol. 23:133–141. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang JC, Sherry RM, Steinberg SM, Topalian
SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton
KE, White DE, et al: Randomized study of high-dose and low-dose
interleukin-2 in patients with metastatic renal cancer. J Clin
Oncol. 21:3127–3132. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Negrier S, Escudier B, Lasset C, Douillard
JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau
M, et al: Recombinant human interleukin-2, recombinant human
interferon alfa-2a, or both in metastatic renal-cell carcinoma.
Groupe Français d'Immunothérapie. N Engl J Med. 338:1272–1278.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Negrier S, Perol D, Ravaud A, Chevreau C,
Bay JO, Delva R, Sevin E, Caty A and Escudier B: French
Immunotherapy Intergroup: Medroxyprogesterone, interferon alfa-2a,
interleukin 2, or combination of both cytokines in patients with
metastatic renal carcinoma of intermediate prognosis: Results of a
randomized controlled trial. Cancer. 110:2468–2477. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Coppin C, Porzsolt F, Awa A, Kumpf J,
Coldman A and Wilt T: Immunotherapy for advanced renal cell cancer.
Cochrane Database Syst Rev. CD0014252005.PubMed/NCBI
|
|
9
|
Coppin C, Le L, Porzsolt F and Wilt T:
Targeted therapy for advanced renal cell carcinoma. Cochrane
Database Syst Rev: CD006017. 2008. View Article : Google Scholar
|
|
10
|
Motzer RJ, Mazumdar M, Bacik J, Berg W,
Amsterdam A and Ferrara J: Survival and prognostic stratification
of 670 patients with advanced renal cell carcinoma. J Clin Oncol.
17:2530–2540. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Motzer RJ, Bacik J, Murphy BA, Russo P and
Mazumdar M: Interferon-alfa as a comparative treatment for clinical
trials of new therapies against advanced renal cell carcinoma. J
Clin Oncol. 20:289–296. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mekhail TM, Abou-Jawde RM, Boumerhi G,
Malhi S, Wood L, Elson P and Bukowski R: Validation and extension
of the Memorial Sloan-Kettering prognostic factors model for
survival in patients with previously untreated metastatic renal
cell carcinoma. J Clin Oncol. 23:832–841. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Teishima J, Kobatake K, Hayashi T, Seno Y,
Ikeda K, Nagamatsu H, Hieda K, Shoji K, Miyamoto K, Inoue S, et al:
Prognostic significance of C-reactive protein in patients with
intermediate-risk metastatic renal cell carcinoma treated with
molecular targeted therapy. Oncol Lett. 8:881–885. 2014.PubMed/NCBI
|
|
14
|
Yasuda Y, Saito K, Yuasa T, Kitsukawa S,
Urakami S, Yamamoto S, Yonese J, Takahashi S and Fukui I:
Prognostic impact of pretreatment C-reactive protein for patients
with metastatic renal cell carcinoma treated with tyrosine kinase
inhibitors. Int J Clin Oncol. 18:884–889. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Patil S, Figlin RA, Hutson TE, Michaelson
MD, Négrier S, Kim ST, Huang X and Motzer RJ: Prognostic factors
for progression-free and overall survival with sunitinib targeted
therapy and with cytokine as first-line therapy in patients with
metastatic renal cell carcinoma. Ann Oncol. 22:295–300. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Beuselinck B, Oudard S, Rixe O, Wolter P,
Blesius A, Ayllon J, Elaidi R, Schöffski P, Barrascout E, Morel A,
et al: Negative impact of bone metastasis on outcome in clear-cell
renal cell carcinoma treated with sunitinib. Ann Oncol. 22:794–800.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Seidel C, Busch J, Weikert S, Steffens S,
Bokemeyer C and Grünwald V: Tumour shrinkage measured with first
treatment evaluation under VEGF-targeted therapy as prognostic
marker in metastatic renal cell carcinoma (mRCC). Br J Cancer.
109:2998–3004. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
|
|
19
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kwon WA, Cho IC, Yu A, Nam BH, Joung JY,
Seo HK, Lee KH and Chung J: Validation of the MSKCC and Heng risk
criteria models for predicting survival in patients with metastatic
renal cell carcinoma treated with sunitinib. Ann Surg Oncol.
20:4397–4404. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik
C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sternberg CN, Davis ID, Mardiak J,
Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA,
Kavina A, et al: Pazopanib in locally advanced or metastatic renal
cell carcinoma: Results of a randomized phase III trial. J Clin
Oncol. 28:1061–1068. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Choueiri TK, Garcia JA, Elson P, Khasawneh
M, Usman S, Golshayan AR, Baz RC, Wood L, Rini BI and Bukowski RM:
Clinical factors associated with outcome in patients with
metastatic clear-cell renal cell carcinoma treated with vascular
endothelial growth factor-targeted therapy. Cancer. 110:543–550.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Heng DY, Xie W, Regan MM, Warren MA,
Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, et al:
Prognostic factors for overall survival in patients with metastatic
renal cell carcinoma treated with vascular endothelial growth
factor-targeted agents: Results from a large, multicenter study. J
Clin Oncol. 27:5794–5799. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Manola J, Royston P, Elson P, McCormack
JB, Mazumdar M, Négrier S, Escudier B, Eisen T, Dutcher J, Atkins
M, et al: Prognostic model for survival in patients with metastatic
renal cell carcinoma: Results from the international kidney cancer
working group. Clin Cancer Res. 17:5443–5450. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Grassi P, Verzoni E, Porcu L, Testa I,
Iacovelli R, Torri V, Braud Fd and Procopio G: Targeted therapies
in advanced renal cell carcinoma: The role of metastatic sites as a
prognostic factor. Future Oncol. 10:1361–1372. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Busch J, Seidel C, Weikert S, Wolff I,
Kempkensteffen C, Weinkauf L, Hinz S, Magheli A, Miller K and
Grünwald V: Intrinsic resistance to tyrosine kinase inhibitors is
associated with poor clinical outcome in metastatic renal cell
carcinoma. BMC Cancer. 11:2952011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Heng DY, Mackenzie MJ, Vaishampayan UN,
Bjarnason GA, Knox JJ, Tan MH, Wood L, Wang Y, Kollmannsberger C,
North S, et al: Primary anti-vascular endothelial growth factor
(VEGF)-refractory metastatic renal cell carcinoma: Clinical
characteristics, risk factors, and subsequent therapy. Ann Oncol.
23:1549–1555. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Seidel C, Busch J, Weikert S, Steffens S,
Fenner M, Ganser A and Grünwald V: Progression free survival of
first line vascular endothelial growth factor-targeted therapy is
an important prognostic parameter in patients with metastatic renal
cell carcinoma. Eur J Cancer. 48:1023–1030. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Heng DY, Xie W, Bjarnason GA, Vaishampayan
U, Tan MH, Knox J, Donskov F, Wood L, Kollmannsberger C, Rini BI
and Choueiri TK: Progression-free survival as a predictor of
overall survival in metastatic renal cell carcinoma treated with
contemporary targeted therapy. Cancer. 117:2637–2642. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ko JJ, Choueiri TK, Rini BI, Lee JL,
Kroeger N, Srinivas S, Harshman LC, Knox JJ, Bjarnason GA,
MacKenzie MJ, et al: First-, second-, third-line therapy for mRCC:
Benchmarks for trial design from the IMDC. Br J Cancer.
110:1917–1922. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Peña C, Lathia C, Shan M, Escudier B and
Bukowski RM: Biomarkers predicting outcome in patients with
advanced renal cell carcinoma: Results from sorafenib phase III
treatment approaches in renal cancer global evaluation trial. Clin
Cancer Res. 16:4853–4863. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zurita AJ, Jonasch E, Wang X, Khajavi M,
Yan S, Du DZ, Xu L, Herynk MH, McKee KS, Tran HT, et al: A cytokine
and angiogenic factor (CAF) analysis in plasma for selection of
sorafenib therapy in patients with metastatic renal cell carcinoma.
Ann Oncol. 23:46–52. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tran HT, Liu Y, Zurita AJ, Lin Y,
Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN,
Amado RG, et al: Prognostic or predictive plasma cytokines and
angiogenic factors for patients treated with pazopanib for
metastatic renal-cell cancer: A retrospective analysis of phase 2
and phase 3 trials. Lancet Oncol. 13:827–837. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hegde PS, Jubb AM, Chen D, Li NF, Meng YG,
Bernaards C, Elliott R, Scherer SJ and Chen DS: Predictive impact
of circulating vascular endothelial growth factor in four phase III
trials evaluating bevacizumab. Clin Cancer Res. 19:929–937. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tsavachidou-Fenner D, Tannir N, Tamboli P,
Liu W, Petillo D, Teh B, Mills GB and Jonasch E: Gene and protein
expression markers of response to combined antiangiogenic and
epidermal growth factor targeted therapy in renal cell carcinoma.
Ann Oncol. 21:1599–1606. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Muriel L, ópez C, Esteban E, Astudillo A,
Pardo P, Berros JP, Izquierdo M, Crespo G, Fonseca PJ, Sanmamed M
and Martínez-Camblor P: Predictive factors for response to
treatment in patients with advanced renal cell carcinoma. Invest
New Drugs. 30:2443–2449. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jonasch E, Corn P, Pagliaro LC, Warneke
CL, Johnson MM, Tamboli P, Ng C, Aparicio A, Ashe RG, Wright JJ and
Tannir NM: Upfront, randomized, phase 2 trial of sorafenib versus
sorafenib and low-dose interferon alfa in patients with advanced
renal cell carcinoma: Clinical and biomarker analysis. Cancer.
116:57–65. 2010.PubMed/NCBI
|
